# Martin Reck

Source: https://onco.cc/people/martin-reck/  
OnCo record `martin-reck` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led KEYNOTE-024, the trial that made pembrolizumab alone first-line therapy for PD-L1-high lung cancer.

## Summary

Martin Reck (LungenClinic Grosshansdorf, Germany) was principal investigator of KEYNOTE-024, which showed pembrolizumab beats platinum chemotherapy in NSCLC with PD-L1 of 50% or more, the first time a checkpoint inhibitor replaced chemotherapy first line. He has led IMpower150 and numerous SCLC immunotherapy trials and has chaired ESMO's lung cancer guideline group.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lung; immunotherapy; trialist
- Role: Head of Thoracic Oncology, LungenClinic Grosshansdorf
- Specialisms: Lung cancer immunotherapy; First-line NSCLC therapy; Small-cell lung cancer

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Reck%20M%5BAuthor%5D%20pembrolizumab%20lung

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [LungenClinic Grosshansdorf](https://onco.cc/institutions/lungenclinic-grosshansdorf/), [nationales Netzwerk Genomische Medizin Lungenkrebs](https://onco.cc/institutions/nngm/)
- trials: [eXalt3](https://onco.cc/trials/nct02767804/), [KEYNOTE-024 & KEYNOTE-189](https://onco.cc/trials/keynote-024-189/)
- key papers: [CheckMate 026: first-line nivolumab in stage IV or recurrent non-small-cell lung cancer](https://onco.cc/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/), [Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer](https://onco.cc/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/), [KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer](https://onco.cc/key-papers/paper-keynote-024-nejm-2016/), [KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations](https://onco.cc/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/), [Perioperative durvalumab for resectable non-small-cell lung cancer](https://onco.cc/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/martin-reck.json